Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program - sprookjes - yvandenbroek - TriplyDB

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

http://www.wikidata.org/entity/Q34683835

about

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation Osteosarcoma: Current Treatment and a Collaborative Pathway to Success Eribulin in Cancer Treatment Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis Diagnosis and treatment of Ewing sarcoma of the bone: a review article Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).Drug discovery in paediatric oncology: roadblocks to progress.Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.Future directions in the treatment of osteosarcoma.Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.Advances in therapy for pediatric sarcomas.Advances in emerging drugs for osteosarcoma.Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.Eribulin in advanced liposarcoma and leiomyosarcoma.Metastatic osteosarcoma: a challenging multidisciplinary treatment.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines.Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.Marine Sponge Natural Products with Anticancer Potential: An Updated Review.Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.

P2860

Q26784048-F41A2B5A-FFA7-4C0F-BC0D-C7D7EFBDB2C0 Q26797555-7D39172C-FBC5-443E-A8BF-2811A4169E35 Q26799328-A8F47841-C41B-4C03-AA09-4F93FF4DE968 Q28077780-A90AEB79-AB0D-4B87-ACC0-83F385C0761F Q28085071-74B19EAB-6DB4-455C-84F7-66277BB3D9C0 Q34792334-86A93AB0-AF19-463C-AF99-8D49851A2FB5 Q35684995-D884B5F4-8663-478D-9512-7DDC9A0E7C99 Q36040758-2C6EC3F5-15DD-4AAD-A1FA-346F6850F453 Q36262295-D897266B-1759-4974-85C9-952F73ACDA8E Q36316518-3D1B351A-D337-4DA2-9A8B-37BF93BDD0E7 Q36592309-B6F2DE07-87AE-460F-810A-42EF8D555468 Q36600800-1D2204E4-54DE-4ABE-A637-D1C896A5EEDC Q36742259-4F7C340D-B925-4E0E-92B3-B0404E34AAC3 Q36888962-3DF7DF96-B7F8-4468-9DA4-67488C7DA3F1 Q37699295-04FC631F-097B-461E-AE46-738B0571243F Q38217354-0E4B64F9-AA28-48EF-9362-EFF4A0C9E3FE Q38506118-87331009-D290-4329-9CBE-8865091C4AC8 Q38688042-FB3E5F72-6051-4BDF-9E4C-B0126D1351B4 Q38722807-F8CC2CAC-03B7-49C2-8FB9-5131876D9EAC Q38783252-5AE61A9C-C15A-4F9A-803A-5BD491C70B0A Q38837564-5F6C7878-6D35-4E3B-B460-D51F613CE60B Q38840985-A6D1645F-1116-4863-B7C5-F421AB18B565 Q40129131-B268933F-C8E4-451A-93C1-383A7C221C58 Q41592750-0E556B18-6093-44C0-8D20-92489331A869 Q42843612-F1BCB2F1-669C-46F0-9609-2EDF200044A0 Q43245354-C27F3E75-0E81-40B5-989A-D6BDD4EBE14B Q46023921-33F3233C-B31F-4FB8-94F2-84E8DE90FD7A Q51779979-6D9B023A-DC8C-4A92-90F8-B49E65F17E97

P2860

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

http://www.wikidata.org/entity/Q34683835

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Initial testing (stage 1) of e ...... ic preclinical testing program

@ast

Initial testing (stage 1) of e ...... ic preclinical testing program

@en

Initial testing (stage 1) of e ...... ic preclinical testing program

@nl

type

label

Initial testing (stage 1) of e ...... ic preclinical testing program

@ast

Initial testing (stage 1) of e ...... ic preclinical testing program

@en

Initial testing (stage 1) of e ...... ic preclinical testing program

@nl

prefLabel

Initial testing (stage 1) of e ...... ic preclinical testing program

@ast

Initial testing (stage 1) of e ...... ic preclinical testing program

@en

Initial testing (stage 1) of e ...... ic preclinical testing program

@nl

P1433

Q34683835-7F4472D4-ECFB-43D2-8D08-5CA91BB35F29

P1476

Q34683835-28F97C48-3607-4380-9EA6-BCB1B5B9D302

P2093

Q34683835-389485FD-1B76-48F3-8CEF-60214C1DA754

Q34683835-3B96FDB5-8E40-4C5B-9A54-74979B9D8FD6

Q34683835-59BF03ED-C60B-40F0-9A43-9AA185580AF1

Q34683835-67BF5755-A855-4182-A4CC-A8ECE8279A8B

Q34683835-72BFAF74-931E-47D1-A94C-F6EB6AE2B5A8

Q34683835-7DD0F0BB-D7EF-4C48-A661-17C0A3141FFA

Q34683835-90FBEDF8-4562-46CC-9088-F6FFBB19D5F6

Q34683835-A52F3275-4DD5-4A2A-BF82-BE9D7E9C756B

Q34683835-B807B3FD-3CEA-473D-84BB-FCFEBC7F9E34

Q34683835-DC7A9E3B-3922-4293-8A9F-F6FC4A44E907

P2860

Q34683835-022F086F-B2F6-458A-8A03-FE49CC2FBD5A

Q34683835-033EF107-5835-4AA6-A19B-89DE2E19C24B

Q34683835-07BE0C6C-615D-42BD-B3A9-17D3A96681E3

Q34683835-08A2A34B-A033-494C-9492-ED28C6F51EC8

Q34683835-0AC0AA3E-9616-4064-B29F-CECD6B2CE210

Q34683835-0B1C2528-537B-4503-947C-DCF9213EF149

Q34683835-184B3946-E851-44B6-AF1E-4FED11F5C5A2

Q34683835-1CB95326-C81E-4827-AABA-E2490857E56B

Q34683835-2985CE25-D0D6-408C-8055-2D60997A32F0

Q34683835-3D4616BB-8D07-4BE5-86F0-D0E3F364D24C

P304

Q34683835-5B96F1B4-A84F-479A-81AD-5BABCAF07AA3

P31

Q34683835-65B0ABD5-9F55-4C72-8B00-60BEF3896952

P356

Q34683835-161DE696-D19A-4C73-A105-5C103C6F1FBE

P433

Q34683835-157B26FC-841A-4B3D-8628-699BD51EB722

P478

Q34683835-864BE2F2-4CB1-4F03-859C-013B85301F8F

P577

Q34683835-2805ACFB-D53E-478D-9672-C0E582DFB660

P698

Q34683835-0D6DA37F-E94B-4263-BEE9-30B045B771A2

P932

Q34683835-FCCA9D3C-F4E5-43F4-931F-F333309CA243

P356

P1433

Pediatric Blood & Cancer

P1476

Initial testing (stage 1) of e ...... ic preclinical testing program

@en

P2093

C Patrick Reynolds

http://www.w3.org/2001/XMLSchema#string

Catherine A Billups

http://www.w3.org/2001/XMLSchema#string

Christopher Desjardins

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Hernan Carol

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Min H Kang

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Raushan T Kurmasheva

http://www.w3.org/2001/XMLSchema#string

P2860

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

Microtubules as a target for anticancer drugs

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma.

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.

Eribulin mesylate in patients with refractory cancers: a Phase I study.

P304

1325-1332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24517

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23553917

http://www.w3.org/2001/XMLSchema#string

P932

4263960

http://www.w3.org/2001/XMLSchema#string